Back to Stakeholders

Enterprise Intelligence

Quarterly psychedelic drug-development briefing

Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.

Cayman Chemical is a US biochemical supplier and manufacturer based in Ann Arbor, Michigan, founded in 1980. Through its own operations and its Cayman Pharma cGMP API platform it provides research biochemicals, reference materials and cGMP active pharmaceutical ingredients, including psychedelic compounds supplied for analytical work and clinical-trial pathways.

Manufacturing Snapshot

Established CDMO / Manufacturer

Scope & Capabilities

API ProductionAnalytical / QC TestingCDMO ServicesRegulatory / CMC Support

Supply Use Cases

Clinical TrialsResearch Use

GxP / Compliance

cGMPDEA Controlled-Substance ComplianceISO

Facilities & Access

Combined US and Czech manufacturing footprint via Cayman Chemical and Cayman Pharma.

Capacity Notes

API manufacturing materials describe annual capacity plus scale-up capability for multi-step synthesis programs.

Manufacturing Details

Supported Substances

Cayman API materials cite cGMP psilocybin and psilocin for clinical trials, with development listings including 3,4-MDMA and N,N-DMT.

Quick Facts

Founded
1980
HQ
United States
Website
Visit